Seres Therapeutics Announces Appointment Of Wael Hashad As Chief Commercial Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, announced today that it has appointed Wael Hashad as Chief Commercial Officer and Executive Vice President.

In this newly created role, Hashad will be responsible for all activities related to the anticipated commercialization of the company's products in development, including SER-109, which is currently in a Phase 2 clinical study for recurring Clostridium difficile infection (CDI). He will report to Roger Pomerantz, M.D., President, Chief Executive Officer and Chairman of Seres.

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.